Onkologia Medikoa
Espezialitatea
Complejo Hospitalario de Toledo
Toledo, EspañaComplejo Hospitalario de Toledo -ko ikertzaileekin lankidetzan egindako argitalpenak (16)
2024
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328
2022
-
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79
-
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
Cancers, Vol. 14, Núm. 8
2021
-
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
OncoTargets and Therapy, Vol. 14, pp. 5345-5352
-
Electronic health records and patient registries in medical oncology departments in Spain
Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 31-45
2018
-
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
BMC Cancer, Vol. 18, Núm. 1
-
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308
-
Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study
OncoTargets and Therapy, Vol. 11, pp. 5845-5852
2017
2016
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study
Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711